

UMass Chan licenses RNA-based treatment for fragile X syndrome to QurAlis Corporation
UMass Chan licenses potential RNA-based treatment for fragile X syndrome to QurAlis Corporation.
Category: Graduate School of Biomedical Sciences,School of Medicine,Faculty,Research,Neuroscience,Jonathan K. Watts,RNA Therapeutics Institute,Program in Molecular Medicine,Latest News,Clinical Trials,Top Stories
Read more